New study tracks early signs of pompe disease in newborns
NCT ID NCT03694561
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 20 newborns and children diagnosed with late-onset Pompe disease through newborn screening. Researchers will track their health for up to 4.5 years to document early muscle and joint symptoms, biomarkers, and quality of life. The goal is to learn when to start preventive treatments like enzyme replacement therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors know when to start enzyme replacement therapy in children with late-onset Pompe disease.
- What could go wrong
- This is an observational study with no treatment being tested, so it will not directly improve health. It only gathers information and may not lead to clear guidelines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GAA DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University
Durham, North Carolina, 27705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an oral pill boost muscle strength in pompe disease?
- Hope for pompe patients: could a switch in enzyme therapy slow decline?
- Pompe disease: new study probes hidden nerve damage behind breathing problems
- Heart condition costs under the microscope in massive hospital study
- Pompe disease study aims to unlock immune secrets for better treatment
- Shocking muscles to move: new exercise hope for nerve disease patients